Targeting pulmonary vascular endothelial cells for the treatment of respiratory diseases

• Published in: Frontiers in pharmacology Vol. 13; p. 983816
• Main Authors: Li, Yi-Xuan, Wang, Hong-Bo, Li, Jing, Jin, Jian-Bo, Hu, Jing-Bo, Yang, Chun-Lin
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 30.08.2022
• Subjects: acute lung injury; drug delivery systems; Pharmacology; pneumonia; respiratory diseases; vascular endothelial cells
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2022.983816

Pulmonary vascular endothelial cells (VECs) are the main damaged cells in the pathogenesis of various respiratory diseases and they mediate the development and regulation of the diseases. Effective intervention targeting pulmonary VECs is of great significance for the treatment of respiratory diseases. A variety of cell markers are expressed on the surface of VECs, some of which can be specifically combined with the drugs or carriers modified by corresponding ligands such as ICAM-1, PECAM-1, and P-selectin, to achieve effective delivery of drugs in lung tissues. In addition, the great endothelial surface area of the pulmonary vessels, the “first pass effect” of venous blood in lung tissues, and the high volume and relatively slow blood perfusion rate of pulmonary capillaries further promote the drug distribution in lung tissues. This review summarizes the representative markers at the onset of respiratory diseases, drug delivery systems designed to target these markers and their therapeutic effects.